Solanum xanthocarpum (SX) has been used to treat a variety of diseases, including skin disorders like psoriasis (PSO). SX possesses many pharmacological activities of anti-inflammatory, anti-cancer, immunosuppressive, and healing qualities. However, the multi-target mechanism of SX on PSO still needs clarity. Materials and methods: The Indian Medicinal Plants, Phytochemicals and Therapeutics (IMPPAT) database and the Swiss Target Prediction online tool were used to find the active phytochemical components and their associated target proteins. OMIM and GeneCards databases were used to extract PSO-related targets. A Venn diagram analysis determined the common targets of SX against PSO. Subsequently, the protein–protein interaction (PPI) network and core PPI target analysis were carried out using the STRING network and Cytoscape software. Also, utilising the online Metascape and bioinformatics platform tool, a pathway enrichment analysis of common targets using the Kyoto Encyclopaedia of Genes and Genome (KEGG) and Gene Ontology (GO) databases was conducted to verify the role of targets in biological processes, cellular components and molecular functions with respect to KEGG pathways. Lastly, molecular docking simulations were performed to validate the strong affinity between components of SX and key target receptors. Results: According to the IMPPAT Database information, 8 active SX against PSO components were active. According to the PPI network and core targets study, the main targets against PSO were EGFR, SRC, STAT3, ERBB2, PTK2, SYK, EP300, CBL, TP53, and AR. Moreover, molecular docking simulations verified the binding interaction of phytochemical SX components with their PSO targets. Last but not least, enrichment analysis showed that SX is involved in several biological processes, including peptidyl-tyrosine phosphorylation, peptidyl-tyrosine modification, and peptidyl-serine modification. The relevant KEGG signalling pathways are the PI3K-AKT signalling pathway, the EGFR tyrosine kinase inhibitor resistance pathway, and the MAPK signalling pathway. Conclusion: The network pharmacology technique, which is based on data interpretation and molecular docking simulation techniques, has proven the multi-target function of SX phytoconstituents.

The goal of this investigation is to improve the topical delivery of medicine by preparing and maximizing the potential of a nanotransferosome gel infused with Solanum xanthocarpum methanolic extract (SXE) to provide localized and regulated distribution. Thin-film hydration was used to create SXE-infused nanotransferosomes (SXE-NTFs), and a Box–Behnken design was used to improve them. Phospholipon 90G (X1), cholesterol (X2) and sodium cholate (X3) were chosen as the independent variables, and their effects on vesicle size (Y1), polydispersity index (PDI) (Y2) and the percentage of entrapment efficiency (EE) (Y3) were observed both individually and in combination. For the SXE-NTFs, the vesicle size was 146.3 nm, the PDI was 0.2594, the EE was 82.24 ± 2.64%, the drug-loading capacity was 8.367 ± 0.07% and the drug release rate was 78.86 ± 5.24%. Comparing the antioxidant activity to conventional ascorbic acid, it was determined to be 83.51 ± 3.27%. Ex vivo permeation tests revealed that the SXE-NTF gel (82.86 ± 2.38%) considerably outperformed the SXE gel (35.28 ± 1.62%) in terms of permeation. In addition, it seemed from the confocal laser scanning microscopy (CLSM) picture of the Wistar rat’s skin that the rhodamine-B-loaded SXE-NTF gel had a higher penetration capability than the control. Dermatokinetic studies showed that the SXE-NTF gel had a better retention capability than the SXE gel. According to the experimental results, the SXE-NTF gel is a promising and successful topical delivery formulation.

Six Sigma is a statistical method assists in systemic issue definition, offers tools for monitoring and analysing influencing elements, and suggests changes that are simple to execute. The present study set out to investigate how the pharmaceutical industry's performance changed because of applying six sigma and its methodology demands a strong commitment from top management as well as appropriate training for vital people, also known to as champions and black belts. The article discusses the impact that Six Sigma implementation has on the operations of the pharmaceutical industry and highlights the advantages that organisations as well as consumers might experience because of the findings while also conducting a comparative analysis of the performance of the pharmaceutical industry across various International Organization, before and after the implementation of the methodology. According to the study's outcomes, the performance of the pharmaceutical business is significantly and beneficially impacted by the 6 𝜎 approach.

The methodical strategy known as Quality by Design or QbD has transformed the pharmaceutical sector by emphasising product quality, safety, and efficacy. This method, which is supported by regulatory organisations such as the USFDA and ICH, emphasises the importance of risk management, understanding processes and goods, and predetermined targets. Important elements such the Quality Target Product Profile, Critical Process Parameters, Critical Quality Attributes, control techniques, or knowledge regarding processes all are included in QbD concepts. SThe increasing acceptance of Analytical Quality by Design (AQbD) in the development of methods ensures robust analytical procedures. The regulatory view highlights the significance of QbD in securing product quality through systematic risk-based methods, continuous improvement, and modern technologies like Process Analytical Technology (PAT). This is especially true for the USFDA and ICH.The use of QbD has expanded to a number of industries, such as the food, pharmaceutical, and herbal sectors, proving its adaptability and efficacy in improving product development, production, and quality control. This Review also illustrates certain Case studies that demonstrate the effective use of QbD in fields including the creation of analytical methods, the formulation of polyherbal tablets, and the assessment of food quality. As the pharmaceutical sector moves towards continuous manufacturing, quality by design (QbD) becomes increasingly important for increasing production effectiveness, cutting expenses, and preserving regulatory compliance. All things considered, QbD presents a bright future for producing pharmaceutical items of the highest standard while reducing mistakes and uncertainty in the production process.